Skip to search formSkip to main contentSkip to account menu

Viracept

Known as: Agouron Brand of Nelfinavir Mesylate, Roche Brand of Nelfinavir Mesylate 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

NelfinavirNelfinavir Mesylate
Nelfinavir Oral Tablet [Viracept]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view.
2009
2009
The Viracept-EMS case: impact and outlook.
2008
2008
Trace determination of ethyl methanesulfonate in Viracept 250 mg tablets by gas chromatography-mass spectrometry.
Ethyl methanesulfonate (EMS) is a potential human mutagenic and carcinogenic compound which has been found by Roche laboratories… 
2004
2004
In Vitro Studies of the Effects of HAART Drugs and Excipients on Activity of Digestive Enzymes
AbstractPurpose. Side effects of diarrhea and steatorrhea diminish the therapeutic value of highly active antiretroviral therapy… 
2003
2003
Reconstitución clínica e inmunológica completa tras el tratamiento antirretroviral de gran actividad en un niño infectado verticalmente por el virus de la inmunodeficiencia humana tipo 1 con…
2003
2003
The Preparedness of national secondary school teachers in Nairobi Province to implement HIV/AIDS Education curriculum
xv 
2001
2001
Synthesis of nucleoside analogs and new Tat protein inhibitors
Two studies, concerning the synthesis of original nucleoside analogs regarded as an application of heterochemistry on… 
1997
1997
Nelfinavir (Viracept) approved: fourth protease inhibitor available.
The Food and Drug Administration (FDA) approved nelfinavir (Viracept) for both adult and pediatric use for treatment of HIV… 
1997
1997
Nelfinavir (Viracept) approved: fourth protease inhibitor available.
: The Food and Drug Administration (FDA) approved nelfinavir (Viracept) for both adult and pediatric use for treatment of HIV… 
1995
1995
Advances in protease inhibitors.
  • B. Cheng
  • PI perspective
  • 1995
  • Corpus ID: 24976364
Advances in protease inhibitor clinical studies are discussed for the following inhibitors: Merck MK-639, Abbott ABT-538… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)